ZANIDATAMAB for Oesophageal adenocarcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 42 adverse event reports in the FDA FAERS database where ZANIDATAMAB was used for Oesophageal adenocarcinoma.
Most Reported Side Effects for ZANIDATAMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 49 | 34.5% | 5 | 45 |
| Infusion related reaction | 17 | 12.0% | 0 | 14 |
| Sepsis | 9 | 6.3% | 2 | 9 |
| Hypokalaemia | 8 | 5.6% | 4 | 5 |
| Pneumonia | 8 | 5.6% | 1 | 8 |
| Cerebrovascular accident | 7 | 4.9% | 0 | 7 |
| Decreased appetite | 7 | 4.9% | 0 | 7 |
| Pneumonitis | 7 | 4.9% | 1 | 4 |
| Acute kidney injury | 6 | 4.2% | 1 | 4 |
| Vomiting | 6 | 4.2% | 1 | 6 |
| Asthenia | 5 | 3.5% | 0 | 5 |
| Nausea | 5 | 3.5% | 1 | 5 |
Other Indications for ZANIDATAMAB
Adenocarcinoma gastric (78)
Gastrooesophageal reflux disease (7)
Product used for unknown indication (7)
Prophylaxis (6)
Other Drugs Used for Oesophageal adenocarcinoma
OXALIPLATIN (1,125)
FLUOROURACIL (943)
PEMBROLIZUMAB (423)
NIVOLUMAB (402)
CAPECITABINE (365)
DOCETAXEL (288)
PACLITAXEL (255)
TRASTUZUMAB (253)
LEUCOVORIN (252)
CISPLATIN (242)